《股市简讯》中国康希诺A/H股齐涨，婴幼儿百白破疫苗上市申请获药监局受理

路透中文12-17 10:13

《股市简讯》中国<a href="https://laohu8.com/S/688185">康希诺</a>A/H股齐涨，婴幼儿百白破疫苗上市申请获药监局受理

* 中国疫苗生产商--康希诺H股6185.HK周二早盘涨幅扩大至4%，其A股688185.SS亦一度升2.7%。

* 该公司此前公告称，婴幼儿用吸附无细胞百（组分）白破联合疫苗（DTcP）（2岁以下）的新药上市申请已于近日获得中国国家药监局出具的受理通知书。目前暂无国产组分百白破疫苗获批在中国上市，公司的婴幼儿用DTcP在中国的定位即为进口疫苗的可行替代品。

* 康希诺H股今年迄今劲涨34.6%，同期恒生指数.HSI大幅上扬15.8%。

* 恒生香港上市生物科技指数.HSHKBIO盘中一度跌0.7%。（完）

更多股市简讯请点选CN-CMN-HOT

(发稿徐凯文；审校张喜良)

((kaiwen.xu@thomsonreuters.com))

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492677324?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-17 10:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492677324","market":"us","top_or_hot":-1,"title":"《股市简讯》中国康希诺A/H股齐涨，婴幼儿百白破疫苗上市申请获药监局受理","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》中国<a href=\"https://laohu8.com/S/688185\">康希诺</a>A/H股齐涨，婴幼儿百白破疫苗上市申请获药监局受理</title></head><body><p>* 中国疫苗生产商--康希诺H股<span>6185.HK</span>周二早盘涨幅扩大至4%，其A股<span>688185.SS</span>亦一度升2.7%。</p><p>* 该公司此前公告称，婴幼儿用吸附无细胞百（组分）白破联合疫苗（DTcP）（2岁以下）的新药上市申请已于近日获得中国国家药监局出具的受理通知书。目前暂无国产组分百白破疫苗获批在中国上市，公司的婴幼儿用DTcP在中国的定位即为进口疫苗的可行替代品。</p><p>* 康希诺H股今年迄今劲涨34.6%，同期恒生指数<span>.HSI</span>大幅上扬15.8%。</p><p>* 恒生香港上市生物科技指数<span>.HSHKBIO</span>盘中一度跌0.7%。（完）</p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (发稿 徐凯文；审校 张喜良)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市简讯》中国康希诺A/H股齐涨，婴幼儿百白破疫苗上市申请获药监局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市简讯》中国康希诺A/H股齐涨，婴幼儿百白破疫苗上市申请获药监局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 10:13 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4T3NI04H:1><strong>路透中文</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>《股市简讯》中国康希诺A/H股齐涨，婴幼儿百白破疫苗上市申请获药监局受理* 中国疫苗生产商--康希诺H股6185.HK周二早盘涨幅扩大至4%，其A股688185.SS亦一度升2.7%。* 该公司此前公告称，婴幼儿用吸附无细胞百（组分）白破联合疫苗（DTcP）（2岁以下）的新药上市申请已于近日获得中国国家药监局出具的受理通知书。目前暂无国产组分百白破疫苗获批在中国上市，公司的婴幼儿用DTcP在中国的...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4T3NI04H:1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4T3NI04H:1","article_id":"2492677324","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492677324","pubTimestamp":1734401629,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市简讯》中国康希诺A/H股齐涨，婴幼儿百白破疫苗上市申请获药监局受理* 中国疫苗生产商--康希诺H股6185.HK周二早盘涨幅扩大至4%，其A股688185.SS亦一度升2.7%。* 该公司此前公告称，婴幼儿用吸附无细胞百（组分）白破联合疫苗的新药上市申请已于近日获得中国国家药监局出具的受理通知书。目前暂无国产组分百白破疫苗获批在中国上市，公司的婴幼儿用DTcP在中国的定位即为进口疫苗的可行替代品。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688185":"康希诺","06185":"康希诺生物","BK0239":"医药制造","BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"\"Stock Market Newsletter\" China's CanSino A/H shares rose together, and the application for the marketing of infant DTP vaccine was accepted by the Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":0.9,"06185":0.9},"content_text":"《股市简讯》中国康希诺A/H股齐涨，婴幼儿百白破疫苗上市申请获药监局受理* 中国疫苗生产商--康希诺H股6185.HK周二早盘涨幅扩大至4%，其A股688185.SS亦一度升2.7%。* 该公司此前公告称，婴幼儿用吸附无细胞百（组分）白破联合疫苗（DTcP）（2岁以下）的新药上市申请已于近日获得中国国家药监局出具的受理通知书。目前暂无国产组分百白破疫苗获批在中国上市，公司的婴幼儿用DTcP在中国的定位即为进口疫苗的可行替代品。* 康希诺H股今年迄今劲涨34.6%，同期恒生指数.HSI大幅上扬15.8%。* 恒生香港上市生物科技指数.HSHKBIO盘中一度跌0.7%。（完）更多股市简讯请点选CN-CMN-HOT (发稿 徐凯文；审校 张喜良) ((kaiwen.xu@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492677324"}